| Project/Area Number |
23591546
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
YOKOTA Shumpei 横浜市立大学, 医学(系)研究科(研究院), 教授 (10158363)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
IMAGAWA Tomoyuki 横浜市立大学, 附属病院, 准教授 (20336548)
MIYAMAE Takako 横浜市立大学, 附属病院, 非常勤診療医 (90322354)
KIKUCHI Masako 横浜市立大学, 附属病院, 助教 (90555129)
NOZAWA Tomo 横浜市立大学, 附属病院, 指導診療医 (10588106)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 小児免疫学 / 小児免疫・アレルギー・膠原病学 |
|---|
| Research Abstract |
Growth impairment accompanied with systemic juvenile idiopathic arthritis (sJIA) is thought to be associated with suppression of proliferation of chondrocyte by IL-6, the key cytokine causing systemic inflammation, and suppression of bone extension by corticosteroid. Tocilizumab, anti-IL-6 receptor antibody, was approved in 2008 in Japan, so now bloadly used as treatment for steroid-refractory or -dependent sJIA. We have investigated height and height velocity of 45 sJIA patient administered with TCZ and analyzed correlation between them and several factors such as age, gender, disease duration and corticosteroid exposure, then inverse correlation between standard deviation score for height (HTSDS) and disease duration and strong correlation between reduction of corticosteroid and improvement of height velocity.
|
